

# The inefficacy of antiangiogenic therapies

Domenico Ribatti, 1. a. @

@ corresponding author, & equal contributor

Journal of Angiogenesis Research. 2010; **2**(1):27 | © Ribatti

Received: 8 November 2010 | Accepted: 10 December 2010 | Published: 10 December 2010

Vascular Cell ISSN: 2045-824X

DOI: <https://doi.org/10.1186/2040-2384-2-27>

## Author information

1. Department of Human Anatomy and Histology - University of Bari Medical School; Bari, Italy

[a] [ribatti@anatomia.uniba.it](mailto:ribatti@anatomia.uniba.it)

## Acknowledgements

Supported in part by MIUR (PRIN 2007), Rome, AIRC,

Milan, and Fondazione Cassa di Risparmio di Puglia, Bari, Italy.

## References

- Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971;285(21):1182-1186.
- Teicher BA. A system approach to cancer therapy (antiangiogenesis plus standard cytotoxics → mechanism(s) of interactions. *Cancer Metastasis Rev.* 1996;15(2):247-272.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med.* 2004;350(23):2335-2342.
- Reddy GK, Bukowski RM. Sorafenib: recent update on activity as a single agent in combination with interferon-alpha 2 in patients with advanced-stage renal cell carcinoma. *Clin Genitour Cancer.* 2006;4(4):246-348.
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. *Lancet.* 2006;368(9554):1329-1338.
- Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. *Int J Clin Oncol.* 2006;11(3):209-213.
- Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor targeted therapy. *Clin Cancer Res.* 2008;14(20):6371-6375.
- Shojaei F, Ferrara N. Role of microenvironment in tumor growth and in refractoriness/resistance to antiangiogenic therapies. *Drug Resist Update.* 2008;11(6):219-230.
- Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. *Clin Breast Cancer.* 2003;3(6):421-422.
- Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med.* 2003;349(5):427-434.
- Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med.* 2007;357(26):2666-2676.
- Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol.* 2003;21(1):60-65.
- Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol.* 2006;3(1):24-40.
- Bergers G, Hanahan D. Modes of resistance on antiangiogenic therapy. *Nat Rev Cancer.* 2008;8(8):592-603.
- Ribatti D. Biomarkers of response to angiogenesis inhibitors: an open and unsolved question. *Eur J Cancer.* 2010;46(1):6-8.
- Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. Tumor-associated

- endothelial cells with cytogenetic abnormalities. *Cancer Res.* 2004;64(22):8249-8255.
17. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. *Cancer Res.* 2005;65(7):2507-2510.
  18. Ribatti D. Antiangiogenic therapy accelerates tumor metastasis. *Leuk Res.* 2010.
  19. Paez-Ribes M, Allen A, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell.* 2009;15(3):222-231.
  20. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. *Cancer Cell.* 2009;15(3):232-239.
  21. Grothey A, Sughue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BriTE). *J Clin Oncol.* 2008;26(5706):5326-5344.
  22. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science.* 2005;307(5706):58-62.
  23. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. *Mol Cancer Ther.* 2008;7(1):71-78.
  24. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell.* 2005;8(4):299-309.
  25. Relf M, Lejeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumor growth factor  $\beta$ -1, platelet-derived growth factor, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Res.* 1997;57(5):963-969.

## Copyright & License

*Statement:* Copyright © 2010, Ribatti.

*Holder:* Ribatti

*Licensee:* Publiverse Online S.R.L.

*License: Open Access* This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.



The present article has been published in Vascular Cell journal by Publiverse Online S.R.L.